Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P15088 (
mast cell
)
14,925
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Acidic fibroblast growth factor is a potent mitogen for a variety of cells in culture, including vascular endothelial cells, and is angiogenic in vivo. The complete amino acid sequence of human
brain-derived
acidic fibroblast growth factor has been determined from amino terminal sequence analysis and
carboxypeptidase A
digestion of the whole protein and sequence analyses of peptides generated by tryptic, Staphylococcus aureus V8 protease and cyanogen bromide cleavages. A potential Asn-Gly-Ser glycosylation sequence is present in the human protein. The complete amino acid sequence is compared to that of the equivalent protein purified from bovine brain.
...
PMID:The complete amino acid sequence of human brain-derived acidic fibroblast growth factor. 352 67
A carboxyl-terminus microsequencing method has been developed on the basis of
carboxypeptidase A
digestion and derivatization of released amino acids with phenylisocyanate followed by subsequent high-performance liquid chromatographic analysis of the resulting phenylthiocarbamyl amino acids. This technique has been used to confirm the carboxyl-terminal sequence of bovine
brain-derived
acidic fibroblast growth factor. The method is of general application for the microsequencing of the carboxyl-termini of proteins. Since identification of derivatized amino acids was performed on the entire reaction mixture following digestion, a new chromatographic identification procedure for phenylthiocarbamyl amino acids was developed in order to resolve them from spurious peaks. This procedure can be applicable to amino acid analysis.
...
PMID:High-performance liquid chromatography of phenylthiocarbamyl-amino acids. Application to carboxyl-terminal sequencing of proteins. 369 85
In the present study, the effect of intracerebroventricular (i.c.v.) administration of histamine on food intake of neonatal chicks was examined over 2 h. Histamine (100, 200 or 400 nmol, respectively) was injected in the lateral ventricle of 2-day-old chicks, and cumulative food intakes were measured. i.c.v. injection of histamine significantly inhibited food intake in a dose-dependent manner. In addition, compound 48/80, which causes degranulation of mast cells and release of histamine, or thioperamide, which is an antagonist of the histamine H3 autoreceptor and increases histamine release from histaminergic nerve terminals, was injected i.c.v. to clarify whether
mast cell
- or neuron-derived histamine in the central nervous system of chicks is essential to the feeding inhibition. Central administration of compound 48/80 inhibited food intake with a dose-dependent manner, but thioperamide had no effect on feeding. An inhibitor of
mast cell
degranulation, sodium cromoglycate, somewhat attenuated food intake inhibited by compound 48/80. These results suggest that
brain-derived
mast cells could be a major source of histamine in the inhibition of food intake of neonatal chicks.
...
PMID:Brain-derived mast cells could mediate histamine-induced inhibition of food intake in neonatal chicks. 1070 May 84
Parkinson's disease (PD) is a progressive movement disorder characterized by neuroinflammation and dopaminergic neurodegeneration in the brain. 1-methyl-4-phenylpyridinium (MPP
+
), a metabolite of the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces the release of inflammatory mediators from glial cells and neurons. Glia maturation factor (GMF), a brain proinflammatory protein, MPP
+
,
and
mast cell
-derived inflammatory mediators induce neurodegeneration which eventually leads to PD. However, the precise mechanisms underlying interaction between glial cells, neurons and mast cells in PD still remain elusive. In the present study, mouse bone marrow-derived mast cells (BMMCs) and mouse fetal
brain-derived
mixed glia/neurons, astrocytes and neurons were incubated with MPP
+
, GMF and
mast cell
-derived inflammatory mediators mouse mast cell protease-6 (MMCP-6), MMCP-7 or tryptase/brain-specific serine protease-4 (tryptase/BSSP-4). Inflammatory mediators released from these cells in the culture medium were quantitated by enzyme-linked immunosorbent assay. Neurodegeneration was quantified by measuring total neurite outgrowth following microtubule-associated protein-2 immunocytochemistry. MPP
+
-induced significant neurodegeneration with reduced total neurite outgrowth. MPP
+
induced the release of tryptase/BSSP-4 from the mouse mast cells, and tryptase/BSSP-4 induced chemokine (C-C motif) ligand 2 (CCL2) release from astrocytes and glia/neurons. Overall our results suggest that MPP
+
, GMF, MMCP-6 or MMCP-7 stimulate glia/neurons, astrocytes or neurons to release CCL2 and matrix metalloproteinase-3. Additionally, CD40L expression is increased in BMMCs after incubation with MPP
+
in a co-culture system consisting of BMMCs and glia/neurons. We propose that
mast cell
interaction with glial cells and neurons during neuroinflammation can be explored as a new therapeutic target for PD.
...
PMID:Cross-Talk between Glia, Neurons and Mast Cells in Neuroinflammation Associated with Parkinson's Disease. 2895 15